Conestoga Capital Advisors’s iRadimed IRMD Stock Holding History

Conestoga Capital Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Hold	21,215	–	–	0.04%	66
2025 Q4	$2.06M	Sell	21,215 -6,160	-23%	-$528K	0.03%	65
2025 Q3	$1.95M	Sell	27,375 -80	-0.3%	-$5.33K	0.03%	69
2025 Q2	$1.64M	Hold	27,455	–	–	0.02%	74
2025 Q1	$1.44M	Hold	27,455	–	–	0.02%	75
2024 Q4	$1.51M	Sell	27,455 -100	-0.4%	-$5.26K	0.02%	77
2024 Q3	$1.39M	Hold	27,555	–	–	0.02%	79
2024 Q2	$1.21M	Sell	27,555 -100	-0.4%	-$4.25K	0.02%	86
2024 Q1	$1.22M	Buy	27,655 +11,875	+75%	+$525K	0.02%	86
2023 Q4	$749K	Buy	+15,780	New	+$663K	0.01%	104
2017 Q1	–	Sell	-504,600	Closed	-$5.6M	–	117
2016 Q4	$5.6M	Sell	504,600 -68,285	-12%	-$735K	0.37%	48
2016 Q3	$9.73M	Buy	572,885 +285,050	+99%	+$5.28M	0.67%	46
2016 Q2	$6.26M	Sell	287,835 -33,175	-10%	-$597K	0.46%	47
2016 Q1	$6.15M	Buy	321,010 +181,205	+130%	+$3.47M	0.42%	45
2015 Q4	$3.92M	Buy	+139,805	New	+$3.95M	0.32%	46

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Conestoga Capital Advisors's IRMD Position: Q1 2026 in Review

Conestoga Capital Advisors held its iRadimed (IRMD) position steady in Q1 2026 at 21,215 shares worth $2.04M. The position accounts for 0.04% of the portfolio, ranked #66.

Conestoga Capital Advisors first reported a position in IRMD in Q4 2015 and has held it in 15 quarters since. The position peaked at $9.73M in Q3 2016. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Conestoga Capital Advisors held 21,215 shares of iRadimed worth $2.04M as of Q1 2026.
Conestoga Capital Advisors left its iRadimed share count unchanged in Q1 2026.
iRadimed made up 0.04% of Conestoga Capital Advisors's portfolio in Q1 2026, its #66 holding.
Conestoga Capital Advisors first reported a position in iRadimed in Q4 2015 and has held it in 15 quarters since.
Conestoga Capital Advisors's iRadimed position peaked at $9.73M in Q3 2016.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Conestoga Capital Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.